Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$260.25 USD

260.25
610,602

-2.79 (-1.06%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $260.38 +0.13 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

by Zacks Equity Research

Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.

Zacks Equity Research

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

by Zacks Equity Research

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

by Zacks Equity Research

Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.

Zacks Equity Research

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

by Zacks Equity Research

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

by Zacks Equity Research

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Zacks Equity Research

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.

Zacks Equity Research

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

by Zacks Equity Research

Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.